The effect of sitagliptin on cardiovascular risk profile in Korean patients with type 2 diabetes mellitus: a retrospective cohort study.

The authors pooled data from 42 RCTs to boost the statistical power of data analysis and found a 43% increase in risk of MI and a marginally significant increase in risk of CV mortality among patients with diabetes who received rosiglitazone. 9 These results and the findings from a series of observational studies over the subsequent years led to the 2010 imposition of substantial market restrictions by the FDA on the availability of the medication

also in 26,082 other papers